Consequences of Homocysteine Export and Oxidation in the Vascular System

 

 Buy Article Permissions and Reprints

ABSTRACT

The risk for arteriosclerosis and thrombosis of patients with severe hyperhomocysteinemia is reduced by homocysteine-lowering therapy. Whether this is the case in patients with mild hyperhomocysteinemia remains to be proved. Another challenge for researchers is to establish a satisfying pathological mechanism of the vasotoxicity of a disturbed homocysteine metabolism. Unfortunately, most in vitro studies use physiologically irrelevant concentrations or forms, or both, of homocysteine. The role of the different oxidized and reduced forms of homocysteine in its metabolism has gained little attention.

In the cell, homocysteine is mainly present in its reduced form. In this article export of homocysteine out of the cell is reported to be regulated by a ``reduced-homocysteine carrier.'' In vitro endothelial cells export homocysteine at a constant rate in a folate dose-dependent matter. Even at high-normal folate levels, endothelial cells export homocysteine. As soon as homocysteine is exported out of the cell, it will be oxidized to a disulfide with any compound containing a thiol function or undergo a disulfide exchange reaction, both resulting in formation of disulfides of homocysteine. Consequently, in plasma, about 99% of homocysteine is bound to disulfides. Before homocysteine can be metabolized, it needs to be taken up by the cell via carriers, channels, or receptors recognizing the different homocysteine disulfides. In the cell, the homocysteine disulfides are reduced, liberating homocysteine in its reduced form. Next, homocysteine can be metabolized after binding to the homocysteine-converting enzymes. In particular, the liver and kidney supposedly take up and metabolize significant amounts of homocysteine.

REFERENCES

• 1 Mudd S H, Skovby F, Levy H L. The natural history of homocystinuria due to cystathionine beta-synthase deficiency.  Am J Hum Genet . 1985;  37 1-31
  PubMedGoogle Scholar
• 2 McCully K S. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis.  Am J Pathol . 1969;  56 111-128
  Google Scholar
• 3 Boushey C J, Beresford S A, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.  Probable benefits of increasing folic acid intakes. JAMA . 1995;  274 1049-1057
  Google Scholar
• 4 Refsum H, Ueland P M, Nygard O, Vollset S E. Homocysteine and cardiovascular disease.  Annu Rev Med . 1998;  49 31-62
  CrossrefPubMedGoogle Scholar
• 5 den Heijer M, Koster T, Blom H J. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.  N Engl J Med . 1996;  334 759-762
  Google Scholar
• 6 den Heijer M, Blom H J, Gerrits W B. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?.  Lancet . 1995;  345 882-885
  CrossrefPubMedGoogle Scholar
• 7 Graham I M, Daly L E, Refsum H M. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project.  JAMA . 1997;  277 1775-1781
  CrossrefPubMedGoogle Scholar
• 8 Kluijtmans L A, Boers G H, Verbruggen B. Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis.  Blood . 1998;  91 2015-2018
  PubMedGoogle Scholar
• 9 Willems H PI, Gerrits W BJ, Rozendaal F R. The VITRO trial: Study design.  Neth J Med . 1998;  52 S43
  PubMedGoogle Scholar
• 10 Welch G N, Loscalzo J. Homocysteine and atherothrombosis.  N Engl J Med . 1998;  338 1042-1050
  Google Scholar
• 11 Blom H J, van der Molen E F. Pathobiochemical implications of hyperhomocysteinemia.  Fibrinolysis . 1994;  8 86-87
  PubMedGoogle Scholar
• 12 Banerjee R V, Matthews R G. Cobalamin-dependent methionine synthase.  FASEB J . 1990;  4 1450-1459
  PubMedGoogle Scholar
• 13 Finkelstein J D. The metabolism of homocysteine: pathways and regulation.  Eur J Pediatr . 1998;  S40-44 (S40-44)
  PubMedGoogle Scholar
• 14 Vandermolen E F, Hiipakka M J, Vanlithzanders H. Homocysteine metabolism in endothelial cells of a patient homozygous for cystathionine beta-synthase (CS) deficiency.  Thromb Haemost . 1997;  78 827-833
  PubMedGoogle Scholar
• 15 Christensen B, Refsum H, Vintermyr O, Ueland P M. Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: Methionine loading of non-transformed, transformed, proliferating, and quiescent cells in culture.  J Cell Physiol . 1991;  146 52-62
  CrossrefPubMedGoogle Scholar
• 16 van der Molen E F, van den Heuvel L P, te Poele Pothoff M T. The effect of folic acid on the homocysteine metabolism in human umbilical vein endothelial cells (HUVECs).  Eur J Clin Invest . 1996;  26 304-309
  CrossrefPubMedGoogle Scholar
• 17 Christensen B, Refsum H, Garras A, Ueland P M. Homocysteine remethylation during nitrous oxide exposure of cells cultured in media containing various concentrations of folates.  J Pharmacol Exp Ther . 1992;  261 1096-1105
  PubMedGoogle Scholar
• 18 Refsum H, Guttormsen A B, Fiskerstrand T, Ueland P M. Hyperhomocysteinemia in terms of steady-state kinetics.  Eur J Pediatr . 1998;  S45-S49 (S45-S49)
  PubMedGoogle Scholar
• 19 Ueland P M, Refsum H, Stabler S P. Total homocysteine in plasma or serum: Methods and clinical applications.  Clin Chem . 1993;  39 1764-1779
  PubMedGoogle Scholar
• 20 Willems H P, Bos G M, Gerrits W B. Acidic citrate stabilizes blood samples for assay of total homocysteine.  Clin Chem . 1998;  44 342-345
  PubMedGoogle Scholar
• 21 Ueland P M. Homocysteine species as components of plasma redox thiol status.  Clin Chem . 1995;  41 340-342
  PubMedGoogle Scholar
• 22 Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction.  Clin Chem . 1995;  41 361-366
  PubMedGoogle Scholar
• 23 Hultberg B, Andersson A, Arnadottir M. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure.  Nephron . 1995;  70 62-67
  PubMedGoogle Scholar
• 24 Mansoor M A, Guttormsen A B, Fiskerstrand T. Redox status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia that follows homocysteine administration.  Clin Chem . 1993;  39 980-985
  PubMedGoogle Scholar
• 25 Ueland P M, Mansoor M A, Guttormsen A B. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status-a possible element of the extracellular antioxidant defense system.  J Nutr . 1996;  126 1281S-1284S
  PubMedGoogle Scholar
• 26 Svardal A, Refsum H, Ueland P M. Determination of in vivo protein binding of homocysteine and its relation to free homocysteine in the liver and other tissues of the rat.  J Biol Chem . 1986;  261 3156-3163.
  PubMedGoogle Scholar